HB982 is a Missouri prescription drug payment and pharmacy benefit manager (PBM) reform bill. It repeals and reenacts several sections of state law to regulate how PBMs and health carriers handle prescription drug pricing, pharmacy reimbursement, rebates, cost-sharing, and patient choice. The bill preserves a patient’s freedom to use the pharmacy of their choice, requires written or electronic prescriptions to be transferable to a chosen pharmacy, and prohibits PBMs from steering, restricting, or penalizing covered persons for obtaining prescription services, consultation, or advice from contracted pharmacies.
The bill also limits what patients may be charged at the point of sale by tying payment to the lesser of the plan copay, cash price, or a reimbursement-based amount. It bars PBMs from charging pharmacies certain adjudication fees, from imposing unknown post-adjudication fees except in limited circumstances, and from reducing claim amounts through indirect mechanisms. It adds disclosure and fiduciary-duty language for PBMs, requires notice of conflicts of interest, and directs the Department of Commerce and Insurance to enforce these provisions. In addition, it revises maximum allowable cost (MAC) rules for generic drug reimbursement, requiring more frequent updates, appeal procedures, minimum reimbursement standards, and protections for pharmacies that decline to dispense drugs when reimbursement is below acquisition cost.
HB982 also creates a new section governing cost-sharing for high-cost medications when no generic substitute is available. Health carriers and PBMs would have to count amounts paid by or on behalf of an enrollee toward out-of-pocket maximums and cost-sharing requirements, and they could not design benefits to account for manufacturer assistance programs in a way that disadvantages enrollees. The bill includes an accommodation for health savings account-qualified high-deductible plans and excludes certain collectively bargained plans covered by federal labor law.
The general sentiment reflected by the bill text is consumer- and pharmacy-friendly, with a strong emphasis on transparency, patient access, and limiting PBM practices viewed as restrictive or financially harmful. Because there are no committee transcripts or recorded votes provided, there is no direct evidence of debate or partisan division in the available materials. Based on the structure of the bill, support would likely come from pharmacies, patients, and plan sponsors seeking more transparency, while opposition would likely come from PBMs and possibly insurers concerned about administrative burden, pricing controls, and increased costs.
The main points of contention are likely to be the bill’s restrictions on PBM contracting practices, its limits on reimbursement and fees, and its new disclosure and fiduciary obligations. PBMs may object to the prohibition on steering and post-adjudication fees, the MAC-list update and appeal requirements, and the requirement to treat certain assistance payments as part of cost-sharing. Health carriers and employer plan sponsors may also be concerned about cost impacts and federal preemption issues, especially for self-funded plans and other federally regulated coverage.
HB982 would substantially amend Missouri law governing pharmacy benefit managers, pharmacy reimbursement, and prescription drug cost-sharing. It repeals and reenacts sections 338.015, 376.387, and 376.388, and adds a new section 376.448, thereby expanding state regulation of PBM conduct, pharmacy network contracting, MAC pricing, rebate-related definitions, and enrollee out-of-pocket calculations. The bill would affect PBMs, health carriers, pharmacies, pharmacists, covered persons, and health benefit plan sponsors, while also assigning enforcement authority to the Department of Commerce and Insurance.
No committee testimony or vote record is provided, so the available materials do not show a formal legislative debate or recorded partisan split. The bill’s language suggests a generally favorable posture toward patients and independent pharmacies, with a policy goal of curbing PBM practices perceived as opaque or anti-competitive. In that sense, the bill appears designed to appeal to consumer access and pharmacy reimbursement concerns rather than to preserve existing PBM flexibility.
The likely areas of contention are the bill’s limits on PBM steering, its prohibition on certain fees and post-adjudication adjustments, and its requirements for MAC pricing transparency and reimbursement floors. PBMs and possibly insurers may argue these provisions interfere with contracting and could raise plan costs, while pharmacies and patient advocates are likely to support them as protections against under-reimbursement and restricted pharmacy choice. The new cost-sharing rules for drugs without generic substitutes may also be disputed because they could affect benefit design and the treatment of manufacturer assistance programs.